Pfenex (PFNX) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	8-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	PFNX
Entity Registrant Name	Pfenex Inc.
Entity Central Index Key	1478121
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		23,133,268

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$91,995	$45,722
Accounts and unbilled receivables, net	1,250	1,584
Inventories	21	23
Income tax receivable	385	402
Deferred income taxes	3,281	3,281
Other current assets	2,060	1,753
Total current assets	98,992	52,765
Restricted cash	3,955	3,955
Property and equipment, net	2,477	2,310
Other long term assets	53	53
Intangible assets, net	6,230	6,363
Goodwill	5,577	5,577
Total assets	117,284	71,023
Current liabilities
Accounts payable	1,814	1,129
Accrued liabilities	3,069	2,633
Current portion of deferred revenue	4,005	201
Line of credit obligation	3,813	3,813
Total current liabilities	12,701	7,776
Deferred revenue, less current portion	46,896
Deferred tax liability	3,281	3,281
Other long-term liabilities	80	92
Total liabilities	62,958	11,149
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized ; 20,522,557 and 20,405,066 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	21	21
Additional paid-in capital	173,566	173,141
Accumulated deficit	-119,261	-113,288
Total stockholders' equity	54,326	59,874
Total liabilities and stockholders' equity	$117,284	$71,023

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized	200,000,000	200,000,000
Common stock, shares issued	20,522,557	20,405,066
Common stock, outstanding	20,522,557	20,405,066

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue	$1,975	$2,558
Cost of revenue	1,308	1,908
Gross profit	667	650
Operating expense
Selling, general and administrative	3,891	1,495
Research and development	2,809	678
Total operating expense	6,700	2,173
Loss from operations	-6,033	-1,523
Other income (expense), net	80	-18
Net loss before income taxes	-5,953	-1,541
Income tax expense	-19	-1
Net loss	-5,972	-1,542
Effective preferred stock dividends		-435
Net loss attributable to common stockholders	($5,972)	($1,977)
Net loss per common share basic and diluted	($0.29)	($1.28)
Weighted-average common shares used to compute basic and diluted net loss per share	20,474	1,548

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($5,972)	($1,542)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization	126	116
Amortization of intangible assets	133	133
Stock-based compensation expense	316	8
Changes in operating assets and liabilities
Accounts and unbilled receivables	334	1,361
Inventories	2	5
Other current assets	-307	-231
Other long term assets	-1	95
Accounts payable	685	-253
Accrued expenses	424	226
Deferred revenue	50,700	11
Income tax receivable	17	-3
Net cash provided by (used in) operating activities	46,457	-74
Cash flow from investing activities
Sales/maturities of investments		1,250
Acquisitions of property and equipment	-293	-3
Net cash (used in) provided by investing activities	-293	1,247
Cash flows from financing activities
Restricted cash		-1
Proceeds from exercise of stock options and other stock issuances	109	9
Net cash provided by financing activities	109	8
Net increase in cash and cash equivalents	46,273	1,181
Cash and cash equivalents
Beginning of period	45,722	3,954
End of period	91,995	5,135
Supplemental schedule of cash flow information
Cash paid for interest	26	21
Cash paid for taxes	2	3
Non-cash financing transactions
Accretion of preferred stock redemption value	$0	($5,000)

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies
	Business Activities and Organization
	Pfenex Inc. (“Company” or “Pfenex”) was incorporated in the state of Delaware in 2009. The Company is a clinical-stage biotechnology company engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics, or biosimilars. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis is marketed by Genentech, Inc. a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases. The Company is currently conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, with its collaboration partner, Hospira, Inc. (“Hospira”). Hospira is responsible for determining the need for and timing of any interim analysis for the Phase 1b/2a trial. The Company expects to commence a Phase 3 trial with Hospira in 2016. Hospira will be responsible for the manufacturing and commercialization of PF582 globally upon successful receipt of marketing approval. The Company’s next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b), marketed by Bayer AG for the treatment of multiple sclerosis. The Phase 1 trial for PF530 was initiated in March 2015. The Company believes it is the most advanced in global development of these biosimilar product candidates. In addition to the Company’s two lead product candidates, its pipeline includes five other biosimilar candidates as well as vaccine, generic and next generation biologic candidates. The Company filed the Investigational New Drug (“IND”) for its recombinant anthrax vaccine at the end of 2014.
	The Company’s revenue in the near term is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.
	Reverse Stock Split
	On June 27, 2014, the Company effected a 2.812-for-1 reverse stock split of its common and preferred stock. All share and per share information has been retroactively adjusted to reflect this reverse stock split.
	Initial Public Offering
	In July 2014, the Company completed its initial public offering (“IPO”) in which 8,333,333 shares of common stock at a price of $6.00 per share were issued and sold. Additionally, the Company sold 1,095,751 shares of common stock pursuant to the underwriters’ option to purchase additional shares. The Company received aggregate proceeds of approximately $52.6 million from the sale of shares of common stock, net of underwriters’ discounts and commissions, but before deducting paid and unpaid offering expenses of approximately $2.0 million. In connection with the IPO, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.
	Subsidiary – Pfenex Limited
	In December 2013, to assist with its strategy of approaching the regulatory authorities in the EU for its pipeline products, the Company formed a new entity in the UK. An application for incorporation with the Registrar of Companies for England and Wales was filed and approved for the Company’s subsidiary, Pfenex Limited. There has been no activity in the subsidiary and therefore no intercompany relationship requiring elimination in the condensed consolidated financial statements.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements, which include the Company’s wholly-owned subsidiary, have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.
	Segments
	The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained at the Company’s facility in the United States.
	Use of Estimates
	The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.
	Restricted Cash
	In May 2012, the Company entered into a revolving line of credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”) under which the Company may borrow up to $1.5 million. Additionally, the Company entered into a second line of credit with Wells Fargo in June 2013 under which the Company may borrow up to $2.4 million. The two lines of credit (“LOCs”) are secured by a security interest of first priority in favor of Wells Fargo in all funds deposited in two of the Company’s money market accounts held at Wells Fargo. Restrictions on the money market accounts will be removed when the LOCs are paid in full and have expired. The LOCs are due and payable in full in July 2015.
	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at two major financial institutions as of March 31, 2015 and December 31, 2014. For the Company’s cash position of $96.0 million as of March 31, 2015, which includes restricted cash of $4.0 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance.
	Additional credit risk is related to the Company’s concentration of receivables. As of March 31, 2015 and December 31, 2014, receivables were concentrated among two customers representing 82% and 95% of total net receivables, respectively. For the three month period ended March 31, 2015, revenue was concentrated among three customers representing 67% of total revenues and two customers representing 76% for the three months ended March 31, 2014. There were no supplier concentrations.
	A portion of revenue is earned from sales outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the three months ended March 31, 2015 and 2014 is as follows:
		Three Months Ended
		March 31,
		2015		2014
	(in thousands)	(unaudited)
	US Revenue	$	1,608	$	2,227
	Non-US Revenue		367		331
		$	1,975	$	2,558
	During the three months ended March 31, 2015, revenue earned from non-recurring sales in Japan accounted for 10% of the Company’s revenue. During the three months ended March 31, 2014, no single foreign country accounted for more than 10% of the Company’s revenue.
	Inventories
	Inventories consist of finished goods and are valued at the lower of cost or market. The Company regularly reviews inventories on hand to identify any inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements. No write-downs were recorded during the three months ended March 31, 2015 or the year ended December 31, 2014.
	Revenue
	The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein products which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving milestones and for product royalties.
	The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement.
	Upfront, nonrefundable payments that do not have stand-alone value are recorded as deferred revenue and recognized as revenue over the estimated period of performance. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.
	Revenue under service agreements are recorded as services are performed. These agreements do not require scientific achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.
	The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under its government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable.
	The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. Where separate milestone payments do not meet these criteria, the Company recognizes revenue using a contingency-adjusted performance model over the period of performance. For the three months ended March 31, 2015 and 2014, no revenue in connection with the achievement of milestones has been recognized.
	The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the Company’s price to the buyer is fixed or determinable, and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if: (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. As of March 31, 2015, the Company has had minimal product returns related to reagent protein product sales. However, given the nature of the products, the Company has recorded reserves of $23 thousand and $10 thousand for warranty and return rights at March 31, 2015 and December 31, 2014, respectively. The reserve is a component of accounts and unbilled receivables, net in the accompanying condensed consolidated balance sheets. Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.
	Recently Issued Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU as currently issued will be effective for the Company starting in the first quarter of fiscal year 2018 using one of two retrospective application methods. On April 1, 2015, the FASB voted to propose a one-year deferral to the effective date, but to permit entities to adopt one year earlier if they choose (i.e., the original effective date). The proposal will be subject to the FASB’s due process requirement, which includes a period for public comments. The new standard allows for two methods of adoption: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance. The Company is in the process of determining the adoption method as well as the effects the adoption will have on its condensed consolidated financial statements.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. Fair Value Measurements
	Authoritative guidance defines fair value, establishes a framework for measuring fair value in U.S. GAAP and requires disclosures about fair value measurements.
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
	Level 1	Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at March 31, 2015 and December 31, 2014 included the Company’s cash, cash equivalents and investments in certificates of deposit. There were no Level 1 liabilities;
	Level 2	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at March 31, 2015 or December 31, 2014; and
	Level 3	Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at March 31, 2015 or December 31, 2014.
	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, were determined using the inputs described above and are as follows:
		Total			Fair Value Measurements at Reporting Date Using
					Quoted Prices			Significant		Significant
					in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical Assets			Inputs		(Level 3)
					(Level 1)			(Level 2)
	(in thousands)
	March 31, 2015 (unaudited)
	Cash and money market funds	$	95,950		$	95,950		$	—	$	—
	Certificates of deposit		—			—			—		—
	Total		95,950			95,950			—		—
	Less cash, cash equivalents and restricted cash		(95,950	)		(95,950	)		—		—
	Total investments	$	—		$	—		$	—	$	—
	December 31, 2014
	Cash and money market funds	$	49,677		$	49,677		$	—	$	—
	Certificates of deposit		—			—			—		—
	Total		49,677			49,677			—		—
	Less cash, cash equivalents and restricted cash		(49,677	)		(49,677	)		—		—
	Total investments	$	—		$	—		$	—	$	—
	Cash and money market funds include restricted cash, which is included in non-current assets on the balance sheets.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment
	Property and equipment consisted of the following:
		March 31,			December 31,
		2015			2014
	(in thousands)	(unaudited)
	Furniture and equipment	$	159		$	157
	Computers and IT equipment		198			190
	Purchased software		719			686
	Lab and research equipment		2,959			2,837
	Leasehold improvements		450			348
	Other fixed assets		35			35
	Total property and equipment, gross		4,520			4,253
	Less: accumulated depreciation and amortization		(2,043	)		(1,943	)
	Total property and equipment, net	$	2,477		$	2,310
	Total depreciation and amortization expense was included in selling, general and administrative expenses and research and development in the accompanying Statements of Operations as follows:
		Three months ended
		March 31,
		2015			2014
	(in thousands)	(unaudited)
	Selling, general and administrative	$	69		$	92
	Research and development		57			24
	Total depreciation and amortization expense	$	126		$	116

Notes_Receivable_from_Related_

Notes Receivable from Related Parties	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Notes Receivable from Related Parties	4. Notes Receivable from Related Parties
	On January 21, 2010, the Company issued promissory notes (“Notes”) to certain officers and employees totaling $87 thousand in principal related to the payment of personal taxes associated with the restricted shares of common stock issued to these respective employees as discussed in Note 11—Stock-Based Compensation. The principal balance of the Notes were due together with accrued and unpaid interest on the earliest of: (i) January 21, 2015, (ii) upon the occurrence and during the continuance of an event of default under the Note, (iii) the closing of a corporate event affecting the existing ownership structure, and (iv) the sale of any shares of common stock of the Company held by the maker to a third party. The Notes bore simple interest at 2.45% per annum. In June 2014, the Company’s Board of Directors (“board of directors”) approved the forgiveness of the principal amount and any accrued interest for each of the Notes and to gross up each affected employee’s compensation, in full, for any withholding tax obligations incurred in connection with such Note forgiveness. The total charge of $157 thousand for the write-off of the Notes, interest receivable, and related tax forgiveness was recorded in June 2014.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets
	Intangible assets consisted of the following:
		March 31,			December 31,
		2015			2014
	(in thousands)	(unaudited)
	Customer relationships	$	3,750		$	3,750
	Developed technology		4,400			4,400
	Trade names		910			910
	Gross intangible assets		9,060			9,060
	Less: Accumulated amortization		(2,830	)		(2,697	)
	Total intangible assets, net	$	6,230		$	6,363
	Amortization expense was $0.1 million for the three months ended March 31, 2015 and 2014. Amortization expense is included within selling, general and administrative expense in the accompanying Statements of Operations. As of March 31, 2015, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities
	Accrued liabilities consisted of the following:
		March 31,		December 31,
		2015		2014
	(in thousands)	(unaudited)
	Accrued vacation	$	454	$	379
	Deferred rent		257		247
	Accrued bonuses		295		913
	Other accrued employee-related liabilities		205		125
	Accrued professional fees		373		221
	Accrued supplier liability		395		198
	Accrued subcontractor costs		865		292
	Other accrued liabilities		225		258
		$	3,069	$	2,633

Lines_of_Credit_Obligation

Lines of Credit Obligation	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Lines of Credit Obligation	7. Lines of Credit Obligation
	The Company entered into two Revolving Line of Credit agreements with Wells Fargo, the first of which was entered into in May 2012 (“2012 LOC”) and the second in June 2013 (“2013 LOC”). The maximum capacity for the 2012 LOC and 2013 LOC is $1.5 million and $2.4 million, respectively, for a total capacity of $3.9 million. Both lines of credit are collateralized by money market accounts held at Wells Fargo. The documents governing the credit facilities contain both financial and other covenants. The Company was not in compliance with covenants pertaining to (i) the delivery of its 2012 audit report, which was delivered before May 15, 2014 along with the Company’s 2013 audit report; (ii) the pre-approval for certain capital expenditures; and (iii) the pre-approval required for entering into a lease for a commercial copier/printer. In April 2014, the Company obtained from Wells Fargo a waiver for the covenants and confirmation that the Company may repurchase common stock up to a maximum of $0.5 million. In June 2014, the Company entered into an amendment to the credit facilities which allows the Company to (i) make additional investments in fixed assets in any fiscal year; (ii) incur operating lease expenses in any fiscal year up to $0.6 million; and (iii) declare or pay any dividend or distribution either in cash, stock or any other property, or redeem, retire, repurchase or otherwise acquire any shares of any class of its stock in connection with the Company’s IPO. In January 2015, the Company entered into an amendment which increased the annual limit on operating lease expenses from $0.6 million to $0.9 million. In March 2015, Wells Fargo agreed to extend the maturity date on both lines of credit from April 2015 to July 2015. In April 2015, the Company obtained from Wells Fargo a waiver for the covenants and confirmation that the Company may complete its follow-on offering.
	As of March 31, 2015, the amount drawn down on the lines of credit was $1.4 million and $2.4 million for the 2012 LOC and the 2013 LOC, respectively, for a total outstanding amount of $3.8 million. As of March 31, 2015, the 2012 LOC bore fixed interest rates of 2.00% above LIBOR, or 2.375%, and the 2013 LOC bore interest rates ranging from 2.25% to 2.375%. The Company recognized $22 thousand and $20 thousand of interest expense related to the LOCs for the three months ended March 31, 2015 and 2014, respectively.

Collaborative_Arrangements

Collaborative Arrangements	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangements	8. Collaborative Arrangements
	In February 2015, the Company entered into a development and license agreement with Hospira in which Phase 3 equivalence clinical trial costs for PF582 will be shared, and Hospira will be responsible for manufacturing and commercializing the product. Under the terms of the collaboration, the Company is eligible to receive up to $342 million in one-time payments, including a non-refundable payment for the license agreement of $51 million, which was received in March of 2015 upon receipt of antitrust approval, up to $291 million upon the successful achievement of certain pre-commercial and commercial milestones, and double digit escalating royalties on annual sales of PF582. Accordingly, the Company is recognizing the $51 million over the patent lives, which extend to 2028. In the three months ended March 31, 2015, $141 thousand was recognized as license revenue from Hospira.

Common_Stock_and_Preferred_Sto

Common Stock and Preferred Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Common Stock and Preferred Stock	9. Common Stock and Preferred Stock
	Prior to the completion of its IPO in July 2014, the Company was authorized to issue common stock and Series A-1 and Series A-2 redeemable convertible preferred stock. Immediately prior to the completion of the Company’s IPO, all of the outstanding shares of convertible preferred stock automatically converted into 8,634,857 shares of common stock. The Company issued 1,217,784 shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock immediately prior to the completion of the IPO. Members of the Company’s management team also forfeited an aggregate of 100,000 shares of common stock in connection with the completion of the IPO.
	Common Stock
	Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of other classes of stock outstanding.
	Preferred Stock
	Pursuant to the amended and restated certificate of incorporation filed by the Company immediately prior to the completion of its IPO, the board of directors is authorized to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in the Company’s control or other corporate action.
	Series A-1 and A-2 Redeemable Convertible Preferred Stock
	Prior to July 2014, the Company had Series A-1 and A-2 preferred stock outstanding, which had a contingent redemption feature allowing redemption by the holders. The redeemable convertible preferred stock had been classified as mezzanine equity (outside of permanent equity) on the Company’s balance sheet.
	Series A-1 stock was subject to a cumulative dividend of four percent (4%) compounded quarterly, whether or not declared. Each share of Series A-1 stock was convertible into 0.91966 shares of common stock, subject to adjustments for certain dilutive events. Series A-2 stock was subject to a cumulative dividend of eight percent (8%) compounded quarterly, whether or not declared. Each share of Series A-2 stock was convertible into 1.1406 shares of common stock, subject to adjustments for certain dilutive events.
	All of the Company’s outstanding preferred stock was converted to common stock on July 28, 2014. As of March 31, 2014, no dividends had been declared or paid and cumulative dividends as of March 31, 2014 were as follows:
		Cumulative as of July 28, 2014				Cumulative as of March 31, 2014
	(in thousands, except dividends per share)	Dividends		Dividends		Dividends		Dividends
				per Share				per Share
	Series A-2	$	4,457	$	1.25	$	4,088	$	1.15
	Series A-1		2,850	$	0.57		2,632	$	0.53
		$	7,307			$	6,720

Commitment_to_Repurchase_Stock

Commitment to Repurchase Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Commitment to Repurchase Stock	10. Commitment to Repurchase Stock
	On December 1, 2009, the Company entered into a common stock subscription agreement with three investors (“Investors”) pursuant to which the Company agreed to repurchase a maximum of 423,185 shares of common stock at a price per share of $0.31. Pursuant to the amended and restated subscription agreement, dated May 2, 2014, the Company repurchased all 423,185 shares of common stock at $0.31 price per share immediately prior to the completion of the Company’s IPO in July 2014 for a total cost of $131 thousand.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation
	Summary Stock-Based Compensation Information
	The following table summarizes stock-based compensation expense:
		Three months ended
		March 31,
		2015			2014
	(in thousands)	(unaudited)
	Cost of sales	$	21		$	2
	Research and development		29			2
	Selling, general and administrative		266			4
	Total	$	316		$	8
	Stock-based compensation from:
	Stock options	$	285		$	8
	Employee stock purchase plan		31			0
	Total	$	316		$	8
	Stock-Based Compensation Plans
	The 2009 Equity Incentive Plan (“2009 Plan”) terminated in connection with the Company’s IPO in 2014 and, accordingly, no awards will be granted under the 2009 Plan following the IPO. However, the 2009 Plan will continue to govern outstanding awards granted thereunder. An aggregate of 1.1 million shares of common stock was reserved for issuance under the 2009 Plan. The 2009 Plan provided for the grant of incentive stock options and for the grant of nonstatutory stock options, restricted stock, restricted stock units, and stock appreciation rights to the Company’s employees, directors and consultants. As of March 31, 2015, awards covering 0.8 million shares of common stock were outstanding under the 2009 Plan.
	In July 2014, the board of directors adopted the 2014 Equity Incentive Plan (“2014 Plan”) and the Company’s stockholders approved it. The 2014 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to its employees, directors and consultants and its parent and subsidiary corporations’ employees and consultants. Upon approval, a total of 1,356,219 shares of common stock were reserved for issuance pursuant to the 2014 Plan. In addition, the shares reserved for issuance under the 2014 Plan include 6,424 shares returned to the 2009 Plan as the result of expiration or termination of awards (provided that the maximum number of shares that may be added to the 2014 Plan pursuant to such previously granted awards under the 2009 Plan is 961,755 shares). The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each fiscal year beginning in 2015 and ending with and including the 2018 fiscal year, equal to the least of: (i) 1,356,219 shares; (ii) 2.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the board of directors may determine. Stock options granted to date under the 2009 Plan and the 2014 Plan have a term of ten years from the date of grant, and generally vest over a four-year period. However, in the event that an incentive stock option (“ISO”) granted to a participant who, at the time the ISO is granted, owns stock representing more than 10% of the total combined voting power of all classes of stock of the Company, the term of the ISO shall be five (5) years from the grant date or such shorter term as may be provided in the award agreement. In January 2015, the board of directors approved an increase of 510,126 shares to the number of shares reserved for issuance under the 2014 Plan. During the first quarter of 2015, 512,265 option shares were granted and 45,519 option shares were forfeited under the 2014 Plan. As of March 31, 2015, a total of 1,054,415 shares are available for issuance under the 2014 Plan.
	In July 2014, the board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”) and the stockholders approved it. The ESPP provides eligible employees of the Company with an opportunity to acquire shares of its common stock at a discount. The ESPP permits eligible employees to purchase shares of common stock during consecutive and overlapping 24-month offering periods beginning on the first trading day on or after February 15 and August 15 of each year (“Offering Periods”), unless adjusted by the board of directors or one of its designated committees. Eligible employees may purchase shares of up to 15% of their total compensation per pay period, but may purchase no more than $25,000 in fair market value of common stock in any calendar year and no more than 700 shares of common stock per semi-annual purchase period. The price an employee pays is 85% of the fair market value of common stock. Fair market value is equal to the lesser of the closing price of a share of common stock on either the first or last day of the Offering Period.
	A total of 355,618 shares of common stock were reserved for sale under the ESPP as of December 31, 2014. In addition, the ESPP provides for annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of: (i) 355,618 shares; (ii) 1.5% of the outstanding shares of the common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator. In January 2015, the board of directors approved an increase of 306,075 shares to the number of shares reserved for sale under the ESPP. During the first quarter of 2015, 11,142 shares were purchased under the ESPP. As of March 31, 2015, a total of 650,551 shares are available for sale under the ESPP. During the first quarter of 2015, proceeds of $55 thousand were received for the issuance of shares under the ESPP.
	For the three months ended March 31, 2015 and 2014, the Company recorded compensation expense related to the ESPP of approximately $31 thousand and $0, respectively. Additionally, the Company has issued 11,142 shares through March 31, 2015 related to the ESPP.
	The fair value of the employees’ stock purchase rights granted under the ESPP was estimated using the Black-Scholes option pricing model with the following assumptions:
		Three Months Ended March 31,
		2015			2014
	Risk-free interest rate		Less than 1.00	%		N/A
	Expected term of options (months)		6 - 24			N/A
	Volatility		36.1% - 44.82	%		N/A
	Weighted average grant-date fair value per share	$	2.33			N/A
	Stock Options
	The exercise price of all options granted during the three months ended March 31, 2015 and 2014 was equal to the estimated fair value of the underlying common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period. The following assumptions were used to estimate the fair value of stock options:
		Three Months Ended
		March 31,
		2015		2014
	Risk-free interest rate	1.3% – 1.7%		1.20%
	Expected volatility	52.5% – 53.0%		54.40%
	Expected dividend yield	0.00%		0.00%
	Expected life of options in years	6.0 – 6.1		6.1
	The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Black-Scholes option-pricing model requires multiple subjective inputs, including a measure of expected future volatility. Until the IPO in July 2014, the Company’s stock did not have a readily available market. Consequently, the expected future volatility was based on the historical volatility for comparable publically traded companies over the most recent period commensurate with the estimated expected term of the Company’s stock options. Following the completion of the Company’s IPO in July 2014, the fair value of options granted is based on the closing price of the Company’s common stock on the date of grant as quoted on the NYSE MKT.
	The risk-free interest rate assumption is based upon observed interest rates during the period appropriate for the expected term of the options. The expected term of options granted represents the period of time the options are expected to be outstanding. With the exception of the dividend paid in connection with the conversion of all preferred stock upon the completion of the Company’s IPO, the Company has never declared or paid dividends and has no plans to do so in the foreseeable future. Accordingly, the dividend yield assumption is based on the expectation that the Company will not pay dividends in the future. Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	The following table summarizes the Company’s stock option activity during the three months ended March 31, 2015:
		Number of			Weighted
		Options			Average
					Exercise
					Price
		(in thousands, except weighted
		average exercise price)
	Outstanding at December 31, 2014	$	1,232		$	4.68
	Granted		512			7.72
	Exercised		(106	)		0.49
	Cancelled (forfeited)		(46	)		6.48
	Outstanding at March 31, 2015	$	1,592		$	5.89
	Vested and expected to vest at March 31, 2015	$	1,428		$	5.63
	Vested and exercisable at March 31, 2015	$	497		$	1.02
	The Company received approximately $54 thousand and $9 thousand from stock option exercises during the three months ended March 31, 2015 and 2014, respectively. Options outstanding at March 31, 2015 have a weighted average remaining contractual term of 8.3 years.
	As of March 31, 2015, there was approximately $3.4 million of unrecognized compensation cost related to unvested stock option awards and the weighted average period over which this cost is expected to be recognized is 3.5 years.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes
	During the three months ended March 31, 2015, the Company recorded an income tax expense of $19 thousand, related to alternative minimum taxes. For tax purposes, the Company will recognize all of the $51 million upfront payment from Hospira as income. The Company will have a deferred tax asset for the difference between the income recognized for book and tax. The future reversal of the deferred revenue will provide for a carryback to 2015 for any amounts recognized for books in 2016 and 2017, estimated to be about $8 million. The future reversal of this temporary difference is a source of income when evaluating the deferred tax asset and valuation allowance. The Company’s taxable income, after net operating losses, is estimated to be $4 million for 2015 and no tax provision, other than alternative minimum tax, will be recorded in 2015 since the taxable income is less than the sources of income related to the reversal of the temporary differences arising in the carryback period. No tax expense is expected in the next several years as the Company continues to generate net operating losses and corresponding valuation allowances due to its investments in its lead product candidates and other pipeline products.

Net_Loss_per_Share_of_Common_S

Net Loss per Share of Common Stock	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share of Common Stock	13. Net Loss per Share of Common Stock
	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:
		Three Months Ended
		March 31,
		2015			2014
		(unaudited)
	(in thousands, except per share data)
	Net loss	$	(5,972	)	$	(1,542	)
	Effective preferred stock dividend		—			(435	)
	Net loss attributable to common stockholders	$	(5,972	)	$	(1,977	)
	Weighted average shares used to compute basic and diluted net loss per share		20,474			1,548
	Basic and diluted net loss per common share	$	(0. 29	)	$	(1.28	)
	Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as-if converted method, for convertible securities, if inclusion of these is dilutive. Because the Company has reported a net loss for the three months ended March 31, 2015 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.
	The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding, as their effect would be anti-dilutive:
		March 31,
	(in thousands)	2015			2014
	ESPP		46			—
	Options to purchase common stock		1,592			718

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events
	In April 2015, the Company completed a follow-on public offering pursuant to which it sold 2,610,000 shares of its common stock at a price to the public of $15.50 per share. In addition, certain existing stockholders sold 4,140,000 shares of common stock in the underwritten public offering at the same per-share price. The total proceeds the Company received from the offering were approximately $38.0 million, net of underwriting discounts and commissions of approximately $2.4 million. After deducting estimated offering expenses of approximately $1.0 million, net proceeds to the Company were $37.0 million.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Business Activities and Organization	Business Activities and Organization
	Pfenex Inc. (“Company” or “Pfenex”) was incorporated in the state of Delaware in 2009. The Company is a clinical-stage biotechnology company engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics, or biosimilars. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis is marketed by Genentech, Inc. a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases. The Company is currently conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, with its collaboration partner, Hospira, Inc. (“Hospira”). Hospira is responsible for determining the need for and timing of any interim analysis for the Phase 1b/2a trial. The Company expects to commence a Phase 3 trial with Hospira in 2016. Hospira will be responsible for the manufacturing and commercialization of PF582 globally upon successful receipt of marketing approval. The Company’s next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b), marketed by Bayer AG for the treatment of multiple sclerosis. The Phase 1 trial for PF530 was initiated in March 2015. The Company believes it is the most advanced in global development of these biosimilar product candidates. In addition to the Company’s two lead product candidates, its pipeline includes five other biosimilar candidates as well as vaccine, generic and next generation biologic candidates. The Company filed the Investigational New Drug (“IND”) for its recombinant anthrax vaccine at the end of 2014.
	The Company’s revenue in the near term is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.
Reverse Stock Split	Reverse Stock Split
	On June 27, 2014, the Company effected a 2.812-for-1 reverse stock split of its common and preferred stock. All share and per share information has been retroactively adjusted to reflect this reverse stock split.
Initial Public Offering	Initial Public Offering
	In July 2014, the Company completed its initial public offering (“IPO”) in which 8,333,333 shares of common stock at a price of $6.00 per share were issued and sold. Additionally, the Company sold 1,095,751 shares of common stock pursuant to the underwriters’ option to purchase additional shares. The Company received aggregate proceeds of approximately $52.6 million from the sale of shares of common stock, net of underwriters’ discounts and commissions, but before deducting paid and unpaid offering expenses of approximately $2.0 million. In connection with the IPO, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.
Subsidiary - Pfenex Limited	Subsidiary – Pfenex Limited
	In December 2013, to assist with its strategy of approaching the regulatory authorities in the EU for its pipeline products, the Company formed a new entity in the UK. An application for incorporation with the Registrar of Companies for England and Wales was filed and approved for the Company’s subsidiary, Pfenex Limited. There has been no activity in the subsidiary and therefore no intercompany relationship requiring elimination in the condensed consolidated financial statements.
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements, which include the Company’s wholly-owned subsidiary, have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.
Segments	Segments
	The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained at the Company’s facility in the United States.
Use of Estimates	Use of Estimates
	The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.
Restricted Cash	Restricted Cash
	In May 2012, the Company entered into a revolving line of credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”) under which the Company may borrow up to $1.5 million. Additionally, the Company entered into a second line of credit with Wells Fargo in June 2013 under which the Company may borrow up to $2.4 million. The two lines of credit (“LOCs”) are secured by a security interest of first priority in favor of Wells Fargo in all funds deposited in two of the Company’s money market accounts held at Wells Fargo. Restrictions on the money market accounts will be removed when the LOCs are paid in full and have expired. The LOCs are due and payable in full in July 2015.
Concentrations	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at two major financial institutions as of March 31, 2015 and December 31, 2014. For the Company’s cash position of $96.0 million as of March 31, 2015, which includes restricted cash of $4.0 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance.
	Additional credit risk is related to the Company’s concentration of receivables. As of March 31, 2015 and December 31, 2014, receivables were concentrated among two customers representing 82% and 95% of total net receivables, respectively. For the three month period ended March 31, 2015, revenue was concentrated among three customers representing 67% of total revenues and two customers representing 76% for the three months ended March 31, 2014. There were no supplier concentrations.
	During the three months ended March 31, 2015, revenue earned from non-recurring sales in Japan accounted for 10% of the Company’s revenue. During the three months ended March 31, 2014, no single foreign country accounted for more than 10% of the Company’s revenue.
Inventories	Inventories
	Inventories consist of finished goods and are valued at the lower of cost or market. The Company regularly reviews inventories on hand to identify any inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements. No write-downs were recorded during the three months ended March 31, 2015 or the year ended December 31, 2014.
Revenue	Revenue
	The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein products which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving milestones and for product royalties.
	The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement.
	Upfront, nonrefundable payments that do not have stand-alone value are recorded as deferred revenue and recognized as revenue over the estimated period of performance. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.
	Revenue under service agreements are recorded as services are performed. These agreements do not require scientific achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.
	The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under its government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable.
	The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. Where separate milestone payments do not meet these criteria, the Company recognizes revenue using a contingency-adjusted performance model over the period of performance. For the three months ended March 31, 2015 and 2014, no revenue in connection with the achievement of milestones has been recognized.
	The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the Company’s price to the buyer is fixed or determinable, and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if: (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. As of March 31, 2015, the Company has had minimal product returns related to reagent protein product sales. However, given the nature of the products, the Company has recorded reserves of $23 thousand and $10 thousand for warranty and return rights at March 31, 2015 and December 31, 2014, respectively. The reserve is a component of accounts and unbilled receivables, net in the accompanying condensed consolidated balance sheets. Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU as currently issued will be effective for the Company starting in the first quarter of fiscal year 2018 using one of two retrospective application methods. On April 1, 2015, the FASB voted to propose a one-year deferral to the effective date, but to permit entities to adopt one year earlier if they choose (i.e., the original effective date). The proposal will be subject to the FASB’s due process requirement, which includes a period for public comments. The new standard allows for two methods of adoption: (a) full retrospective adoption, meaning the standard is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance. The Company is in the process of determining the adoption method as well as the effects the adoption will have on its condensed consolidated financial statements.
Fair Value Measurements	Authoritative guidance defines fair value, establishes a framework for measuring fair value in U.S. GAAP and requires disclosures about fair value measurements.
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
	Level 1	Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at March 31, 2015 and December 31, 2014 included the Company’s cash, cash equivalents and investments in certificates of deposit. There were no Level 1 liabilities;
	Level 2	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at March 31, 2015 or December 31, 2014; and
	Level 3	Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at March 31, 2015 or December 31, 2014.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Sales Revenue	A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the three months ended March 31, 2015 and 2014 is as follows:
		Three Months Ended
		March 31,
		2015		2014
	(in thousands)	(unaudited)
	US Revenue	$	1,608	$	2,227
	Non-US Revenue		367		331
		$	1,975	$	2,558

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Cash and Investments Measured at Fair Value on Recurring Basis	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, were determined using the inputs described above and are as follows:
		Total			Fair Value Measurements at Reporting Date Using
					Quoted Prices			Significant		Significant
					in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical Assets			Inputs		(Level 3)
					(Level 1)			(Level 2)
	(in thousands)
	March 31, 2015 (unaudited)
	Cash and money market funds	$	95,950		$	95,950		$	—	$	—
	Certificates of deposit		—			—			—		—
	Total		95,950			95,950			—		—
	Less cash, cash equivalents and restricted cash		(95,950	)		(95,950	)		—		—
	Total investments	$	—		$	—		$	—	$	—
	December 31, 2014
	Cash and money market funds	$	49,677		$	49,677		$	—	$	—
	Certificates of deposit		—			—			—		—
	Total		49,677			49,677			—		—
	Less cash, cash equivalents and restricted cash		(49,677	)		(49,677	)		—		—
	Total investments	$	—		$	—		$	—	$	—

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following:
		March 31,			December 31,
		2015			2014
	(in thousands)	(unaudited)
	Furniture and equipment	$	159		$	157
	Computers and IT equipment		198			190
	Purchased software		719			686
	Lab and research equipment		2,959			2,837
	Leasehold improvements		450			348
	Other fixed assets		35			35
	Total property and equipment, gross		4,520			4,253
	Less: accumulated depreciation and amortization		(2,043	)		(1,943	)
	Total property and equipment, net	$	2,477		$	2,310
	Total depreciation and amortization expense was included in selling, general and administrative expenses and research and development in the accompanying Statements of Operations as follows:
		Three months ended
		March 31,
		2015			2014
	(in thousands)	(unaudited)
	Selling, general and administrative	$	69		$	92
	Research and development		57			24
	Total depreciation and amortization expense	$	126		$	116

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets consisted of the following:
		March 31,			December 31,
		2015			2014
	(in thousands)	(unaudited)
	Customer relationships	$	3,750		$	3,750
	Developed technology		4,400			4,400
	Trade names		910			910
	Gross intangible assets		9,060			9,060
	Less: Accumulated amortization		(2,830	)		(2,697	)
	Total intangible assets, net	$	6,230		$	6,363

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Components of Accrued Liabilities	Accrued liabilities consisted of the following:
		March 31,		December 31,
		2015		2014
	(in thousands)	(unaudited)
	Accrued vacation	$	454	$	379
	Deferred rent		257		247
	Accrued bonuses		295		913
	Other accrued employee-related liabilities		205		125
	Accrued professional fees		373		221
	Accrued supplier liability		395		198
	Accrued subcontractor costs		865		292
	Other accrued liabilities		225		258
		$	3,069	$	2,633

Common_Stock_and_Preferred_Sto1

Common Stock and Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Cumulative Dividends	As of March 31, 2014, no dividends had been declared or paid and cumulative dividends as of March 31, 2014 were as follows:
		Cumulative as of July 28, 2014				Cumulative as of March 31, 2014
	(in thousands, except dividends per share)	Dividends		Dividends		Dividends		Dividends
				per Share				per Share
	Series A-2	$	4,457	$	1.25	$	4,088	$	1.15
	Series A-1		2,850	$	0.57		2,632	$	0.53
		$	7,307			$	6,720

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense:
		Three months ended
		March 31,
		2015			2014
	(in thousands)	(unaudited)
	Cost of sales	$	21		$	2
	Research and development		29			2
	Selling, general and administrative		266			4
	Total	$	316		$	8
	Stock-based compensation from:
	Stock options	$	285		$	8
	Employee stock purchase plan		31			0
	Total	$	316		$	8
Assumptions used to Estimate Fair Value of Employee Stock Purchase Plan	The fair value of the employees’ stock purchase rights granted under the ESPP was estimated using the Black-Scholes option pricing model with the following assumptions:
		Three Months Ended March 31,
		2015			2014
	Risk-free interest rate		Less than 1.00	%		N/A
	Expected term of options (months)		6 - 24			N/A
	Volatility		36.1% - 44.82	%		N/A
	Weighted average grant-date fair value per share	$	2.33			N/A
Assumptions used to Estimate Fair Value of Stock Options	The following assumptions were used to estimate the fair value of stock options:
		Three Months Ended
		March 31,
		2015		2014
	Risk-free interest rate	1.3% – 1.7%		1.20%
	Expected volatility	52.5% – 53.0%		54.40%
	Expected dividend yield	0.00%		0.00%
	Expected life of options in years	6.0 – 6.1		6.1
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity during the three months ended March 31, 2015:
		Number of			Weighted
		Options			Average
					Exercise
					Price
		(in thousands, except weighted
		average exercise price)
	Outstanding at December 31, 2014	$	1,232		$	4.68
	Granted		512			7.72
	Exercised		(106	)		0.49
	Cancelled (forfeited)		(46	)		6.48
	Outstanding at March 31, 2015	$	1,592		$	5.89
	Vested and expected to vest at March 31, 2015	$	1,428		$	5.63
	Vested and exercisable at March 31, 2015	$	497		$	1.02

Net_Loss_per_Share_of_Common_S1

Net Loss per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:
		Three Months Ended
		March 31,
		2015			2014
		(unaudited)
	(in thousands, except per share data)
	Net loss	$	(5,972	)	$	(1,542	)
	Effective preferred stock dividend		—			(435	)
	Net loss attributable to common stockholders	$	(5,972	)	$	(1,977	)
	Weighted average shares used to compute basic and diluted net loss per share		20,474			1,548
	Basic and diluted net loss per common share	$	(0. 29	)	$	(1.28	)
Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding	The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding, as their effect would be anti-dilutive:
		March 31,
	(in thousands)	2015			2014
	ESPP		46			—
	Options to purchase common stock		1,592			718

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended	1 Months Ended
	Jun. 27, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jul. 31, 2014
		Segments
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reverse stock split ratio	0.3556
Common stock, shares issued		20,522,557		20,405,066
Number of operating segments		1
Line of credit facility, Maximum borrowing capacity		$3,900,000
Line of credit, Extended maturity date		2-Jul-15
Restricted cash, Included in Cash position		3,955,000		3,955,000
Inventory write downs		0		0
Revenue recognized		0	0
Product return policy period		30 days
Reagent Protein Product [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warranty reserve accrual		23,000		10,000
Credit Availability Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Cash		96,000,000
Restricted cash, Included in Cash position		4,000,000
Customer Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of customers accounted for receivables		2		2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of customers accounted for revenue		3	2
Concentration of risk percentage		67.00%	76.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage		82.00%		95.00%
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | Foreign Country [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of country accounted			0
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | Japan [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of country accounted		1
Geographic Concentration Risk [Member] | Minimum [Member] | Sales Revenue, Net [Member] | Foreign Country [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage		10.00%	10.00%
Initial Public Offering [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued					8,333,333
Common stock price, per share					$6
Proceeds from issuance initial public offering					52,600,000
Offering expense					2,000,000
Common stock repurchased					423,185
Common stock purchase price					$0.31
Number of shares forfeited					100,000
Initial Public Offering [Member] | Redeemable Preferred to Common Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Convertible preferred stock shares converted to common stock					8,634,857
Initial Public Offering [Member] | Redeemable Convertible Preferred Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock issued in connection with payment of dividends					1,217,784
Underwriters' Option [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Issuance of stock (in shares)					1,095,751
Wells Fargo 2012 LOC [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, Maximum borrowing capacity		1,500,000
Wells Fargo 2013 LOC [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, Maximum borrowing capacity		$2,400,000

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Concentration Risk [Line Items]
Revenue	$1,975	$2,558
Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue	1,975	2,558
Geographic Concentration Risk [Member] | US [Member]
Concentration Risk [Line Items]
Revenue	1,608	2,227
Geographic Concentration Risk [Member] | Non - US [Member]
Concentration Risk [Line Items]
Revenue	$367	$331

Fair_Value_Measurements_Cash_a

Fair Value Measurements - Cash and Investments Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	$95,950	$49,677
Assets fair value disclosure	95,950	49,677
Less cash, cash equivalents and restricted cash	-95,950	-49,677
Total investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	95,950	49,677
Assets fair value disclosure	95,950	49,677
Less cash, cash equivalents and restricted cash	-95,950	-49,677
Total investments	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	$0	$0

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$4,520	$4,253
Less: accumulated depreciation and amortization	-2,043	-1,943
Total property and equipment, net	2,477	2,310
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	159	157
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	198	190
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	719	686
Research and Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	2,959	2,837
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	450	348
Other Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$35	$35

Property_and_Equipment_Depreci

Property and Equipment - Depreciation and Amortization Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	$126	$116
Selling, General and Administrative Expenses [Member]
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	69	92
Research and Development [Member]
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	$57	$24

Notes_Receivable_from_Related_1

Notes Receivable from Related Parties - Additional Information (Detail) (Officers and Employees [Member], USD $)	1 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2015	Jan. 21, 2010
Officers and Employees [Member]
Related Party Transaction [Line Items]
Principal amount of note issued			$87
Debt instrument due date, Description		The principal balance of the Notes were due together with accrued and unpaid interest on the earliest of (i) January 21, 2015, (ii) upon the occurrence and during the continuance of an event of default under the Note, (iii) the closing of a corporate event affecting the existing ownership structure, and (iv) the sale of any shares of common stock of the Company held by the maker to a third party.
Interest rate			2.45%
Charge for write-offs	$157

Intangible_Assets_Summary_of_I

Intangible Assets - Summary of Intangible Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	$9,060	$9,060
Less: Accumulated amortization	-2,830	-2,697
Total intangible assets, net	6,230	6,363
Trade Names [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	910	910
Customer Relationships [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	3,750	3,750
Developed Technology [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	$4,400	$4,400

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$133	$133
Expected Tax Expenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	500
Selling, General and Administrative Expenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$100	$100

Accrued_Liabilities_Components

Accrued Liabilities - Components of Accrued Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Accrued vacation	$454	$379
Deferred rent	257	247
Accrued bonuses	295	913
Other accrued employee-related liabilities	205	125
Accrued professional fees	373	221
Accrued supplier liability	395	198
Accrued subcontractor costs	865	292
Other accrued liabilities	225	258
Total accrued liabilities	$3,069	$2,633

Lines_of_Credit_Obligation_Add

Lines of Credit Obligation - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2015	Jun. 30, 2014	Apr. 30, 2014	Dec. 31, 2014
Line of Credit Facility [Line Items]
Line of credit facility, Maximum borrowing capacity	$3,900,000
Line of credit facility, covenant compliance	The Company was not in compliance with covenants pertaining to (i) the delivery of its 2012 audit report, which was delivered before May 15, 2014 along with the Company's 2013 audit report; (ii) the pre-approval for certain capital expenditures; and (iii) the pre-approval required for entering into a lease for a commercial copier/printer.
Line of credit covenant description	In June 2014, the Company entered into an amendment to the credit facilities which allows the Company to (i) make additional investments in fixed assets in any fiscal year; (ii) incur operating lease expenses in any fiscal year up to $0.6 million; and (iii) declare or pay any dividend or distribution either in cash, stock or any other property, or redeem, retire, repurchase or otherwise acquire any shares of any class of its stock in connection with the Company's IPO.
Line of credit, Extended maturity date	2-Jul-15
Line of credit total outstanding amount	3,813,000					3,813,000
Interest expense	22,000	20,000
Maximum [Member]
Line of Credit Facility [Line Items]
Line of credit covenant, common stock repurchase allowed					500,000
Line of credit covenant, operating lease expenses allowed to be incurred			900,000	600,000
Wells Fargo 2012 LOC [Member]
Line of Credit Facility [Line Items]
Line of credit facility, Maximum borrowing capacity	1,500,000
Line of credit total outstanding amount	1,400,000
Line of credit bearing a fixed interest rate	2.38%
Wells Fargo 2012 LOC [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit facility, basis spread	2.00%
Wells Fargo 2013 LOC [Member]
Line of Credit Facility [Line Items]
Line of credit facility, Maximum borrowing capacity	2,400,000
Line of credit total outstanding amount	$2,400,000
Wells Fargo 2013 LOC [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Line of credit bearing a fixed interest rate	2.38%
Wells Fargo 2013 LOC [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Line of credit bearing a fixed interest rate	2.25%

Collaborative_Arrangements_Add

Collaborative Arrangements - Additional Information (Detail) (Collaborative Arrangement, Product PF582 [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Feb. 28, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Patent lives expiration year	2028
License revenue recognized	$141,000
Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible one time payment receivable under collaboration agreements		342,000,000
Milestone payments receivable		291,000,000
Up-front Payment Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received	$51,000,000

Common_Stock_and_Preferred_Sto2

Common Stock and Preferred Stock - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 31, 2014	Dec. 31, 2014
	Vote
Class of Stock [Line Items]
Votes entitled for every common stock	1
Preferred stock, shares authorized	10,000,000			10,000,000
Dividend declared or paid		$0
Initial Public Offering [Member]
Class of Stock [Line Items]
Number of shares forfeited			100,000
Initial Public Offering [Member] | Redeemable Preferred to Common Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock shares converted to common stock			8,634,857
Preferred Stock Series A-1 [Member]
Class of Stock [Line Items]
Preferred stock dividend rate, cumulative percentage	4.00%
Preferred stock conversion ratio for each share	0.91966
Preferred Stock Series A-2 [Member]
Class of Stock [Line Items]
Preferred stock dividend rate, cumulative percentage	8.00%
Preferred stock conversion ratio for each share	1.1406
Redeemable Convertible Preferred Stock [Member] | Initial Public Offering [Member]
Class of Stock [Line Items]
Common stock issued in connection with payment of dividends			1,217,784

Common_Stock_and_Preferred_Sto3

Common Stock and Preferred Stock - Summary of Cumulative Dividends (Detail) (USD $)	Jul. 28, 2014	Mar. 31, 2014
In Thousands, except Per Share data, unless otherwise specified
Dividends Payable [Line Items]
Dividends	$7,307	$6,720
Preferred Stock Series A-2 [Member]
Dividends Payable [Line Items]
Dividends	4,457	4,088
Dividends per Share	$1.25	$1.15
Preferred Stock Series A-1 [Member]
Dividends Payable [Line Items]
Dividends	$2,850	$2,632
Dividends per Share	$0.57	$0.53

Commitment_to_Repurchase_Stock1

Commitment to Repurchase Stock - Additional Information (Detail) (Common Stock [Member], USD $)	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Jul. 31, 2014	Dec. 01, 2009
Equity, Class of Treasury Stock [Line Items]
Common stock purchase price	$0.31
Common stock repurchased	423,185
Total cost of repurchase	$131
Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Number of shares authorized to be repurchased		423,185
Common stock price, per share		$0.31

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$316	$8
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	21	2
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	29	2
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	266	4
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	285	8
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$31	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		1 Months Ended
	Jul. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, granted		512,000
Outstanding options		1,592,000			1,232,000
share based plan ten years date of grant		Annual increase on the first day of each fiscal year beginning in 2015 and ending with and including the 2018 fiscal year, equal to the least of (i) 1,356,219 shares; (ii) 2.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the board of directors may determine.
Annually shares increase percent	2.50%
Option share,forfeited		46,000
Shares annual increase terms under ESPP		Annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of (i) 355,618 shares; (ii) 1.5% of the outstanding shares of the common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator.
Annually shares increase percent under ESPP	1.50%
Stock based compensation expense		$316,000	$8,000
Proceeds from exercise of stock options		54,000			9,000
Unrecognized compensation cost related to unvested stock options		3,400,000
Unrecognized compensation cost related to unvested stock options, weighted average period for recognition		3 years 6 months
2009 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, granted		0
Shares reserved for issuance		1,100,000
Outstanding options		800,000
Share-based compensation arrangement by share-based payment award, award vesting period		4 years
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, granted		512,265
Shares reserved for issuance	1,356,219	1,054,415
Increase (decrease) in shares reserved for issuance		-6,424		510,126
share based plan ten years date of grant		Stock options granted to date under the 2009 Plan and the 2014 Plan have a term of ten years from the date of grant
Option share,forfeited		45,519
2009 and 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term		10 years
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase (decrease) in shares reserved for issuance				306,075
Share based awards description		The ESPP provides eligible employees of the Company with an opportunity to acquire shares of its common stock at a discount. The ESPP permits eligible employees to purchase shares of common stock during consecutive and overlapping 24-month offering periods beginning on the first trading day on or after February 15 and August 15 of each year (bOffering Periodsb), unless adjusted by the board of directors or one of its designated committees.
Maximum fair market value of condition		25,000
Maximum shares employee can purchase		15.00%
Maximum number of common stock purchased in semi annual periods		700
Percentage on market value of common stock		85.00%
Offering period expiration date		15-Feb-16
Shares available for sale		650,551
Shares purchased under ESPP		11,142
Proceeds from issuance of shares under ESPP		55,000
Stock based compensation expense		31,000	0
Shares issued under ESPP		11,142
Incentive Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term		5 years
Percentage of voting power		10.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term		8 years 3 months 18 days
Stock based compensation expense		$285,000	$8,000
Maximum [Member] | Scenario, May be added to the 2014 Plan [Member] | 2009 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of previously granted shares that can be added		961,755

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions used to Estimate Fair Value of Stock Options (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	1.30%
Risk-free interest rate, maximum	1.70%
Risk-free interest rate		1.20%
Expected life of options in years		6 years 1 month 6 days
Expected volatility, minimum	52.50%
Expected volatility, maximum	53.00%
Expected volatility		54.40%
Expected dividend yield	0.00%	0.00%
Employee Stock Purchase Plan ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, maximum			1.00%
Expected volatility, minimum			36.10%
Expected volatility, maximum			44.82%
Weighted average grant-date fair value per share			$2.33
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years	6 years
Minimum [Member] | Employee Stock Purchase Plan ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years			6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years	6 years 1 month 6 days
Maximum [Member] | Employee Stock Purchase Plan ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years			24 months

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Option Transactions under Plan (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Options, beginning balance	1,232
Number of options, granted	512
Number of Options, Exercised	-106
Number of Options, Cancelled (forfeited)	-46
Number of Options, ending balance	1,592
Number of Options, Vested and expected to vest at March 31, 2015	1,428
Number of Options, Vested and exercisable at March 31, 2015	497
Weighted Average Exercise Price, Outstanding, beginning balance	$4.68
Weighted Average Exercise Price, Granted	$7.72
Weighted Average Exercise Price, Exercised	$0.49
Weighted Average Exercise Price, Cancelled (forfeited)	$6.48
Weighted Average Exercise Price, Outstanding, ending balance	$5.89
Weighted Average Exercise Price, Vested and expected to vest at March 31, 2015	$5.63
Weighted Average Exercise Price, Vested and exercisable at March 31, 2015	$1.02

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2015
Income Tax Contingency [Line Items]
Income tax expense	$19,000	$1,000
Upfront payment for tax purposes	51,000,000
Deferred revenue	8,000,000
Estimated taxable income after net operating losses	-5,953,000	-1,541,000
Expected Tax Expenses [Member]
Income Tax Contingency [Line Items]
Income tax expense			0
Estimated taxable income after net operating losses			$4,000,000

Recovered_Sheet1

Net Loss Per Share of Common Stock - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss	($5,972)	($1,542)
Effective preferred stock dividend		-435
Net loss attributable to common stockholders	($5,972)	($1,977)
Weighted average shares used to compute basic and diluted net loss per share	20,474	1,548
Basic and diluted net loss per common share	($0.29)	($1.28)

Recovered_Sheet2

Net Loss Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from computation of diluted shares outstanding	46
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from computation of diluted shares outstanding	1,592	718

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Jul. 31, 2014	Apr. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Common stock, shares issued			20,522,557	20,405,066
Initial Public Offering [Member]
Subsequent Event [Line Items]
Common stock, shares issued	8,333,333
Common stock price, per share	$6
Proceeds from issuance initial public offering	$52.60
Offering expense	2
Underwriters' Option [Member]
Subsequent Event [Line Items]
Issuance of stock (in shares)	1,095,751
Subsequent Event [Member] | Initial Public Offering [Member]
Subsequent Event [Line Items]
Common stock, shares issued		2,610,000
Common stock price, per share		$15.50
Proceeds from issuance initial public offering		38
Proceeds from underwriters		2.4
Offering expense		1
Net Proceeds from issuance initial public offering		$37
Subsequent Event [Member] | Underwriters' Option [Member]
Subsequent Event [Line Items]
Issuance of stock (in shares)		4,140,000